Full-Time

Senior Analyst

Netsuite or Coupa

Confirmed live in the last 24 hours

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Develops treatments for neurological disorders

Compensation Overview

$101.2k - $146.6k/yr

+ Bonus + Equity Incentive Program

Senior

Company Does Not Provide H1B Sponsorship

San Diego, CA, USA

Category
Project Management
Business Development
Business & Strategy
Required Skills
NetSuite
Coupa
Requirements
  • Bachelor’s degree in computer science, or other related field or equivalent experience and 4+ years of experience in implementing and maintaining on-premises/cloud-based, integrated/stand-alone Systems and Software. Pharmaceutical and/or Life Sciences experience preferred OR
  • Master’s degree in a related field and 2+ years of related experience
  • Understands key business drivers and uses this understanding to accomplish work
  • Has strong understanding of business processes, procedures and systems used to accomplish the work, considers and recognizes downstream impact on other functional areas
  • Typically interacts with high-level Individual Contributors and Managers
  • Proficient with tools and processes that support work conducted by functional area
  • Ability to collaborate as part of a cross-functional team; may lead and train lower levels
  • Normally receives little instruction on day-to-day work, general instructions on new assignments
  • Strong communication, problem-solving, analyzing skills
  • Detail oriented yet can see broader picture
  • Ability to prioritize and lead across differing deadlines, with a high degree of accuracy and efficiency
  • NetSuite
  • Coupa
  • Knowledge of industry trends, best practices & operating principles
  • Proven success implementing and / or maintaining SaaS software for one or more of the following functional areas: Finance, Accounting or Procurement
  • Integration experience a plus (Workato, etc.)
  • Familiarity with Computer System Validation, 21 CFR Part 11, Annex 11; general GxP experience a plus
Responsibilities
  • NetSuite and Coupa configurations, optimizations, integrations and general problem-solving
  • Work closely with cross-functional teams to solve complex business challenges
  • Design and implement new processes that maximize the potential of NetSuite and Coupa and other financial related applications (Sovos, Planful)
  • Leverage advanced features like SuiteScripts, Saved Searches and Custom Records
Desired Qualifications
  • Pharmaceutical and/or Life Sciences experience preferred
  • Integration experience a plus (Workato, etc.)
  • General GxP experience a plus
Neurocrine Biosciences

Neurocrine Biosciences

View

Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company has a range of FDA-approved medications for conditions such as tardive dyskinesia, Huntington's disease-related chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. Their products work by targeting specific pathways in the brain and body to alleviate symptoms associated with these disorders. Unlike many competitors, Neurocrine emphasizes a deep understanding of the connections between brain and body systems, which informs their research and development efforts. The company's goal is to relieve suffering for patients with unmet medical needs by providing effective treatments for complex conditions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • CRENESSITY's success in CAH could lead to market leadership in glucocorticoid alternatives.
  • Partnership with Nxera enhances Neurocrine's muscarinic agonist portfolio for neuropsychiatric disorders.
  • Share repurchase program reflects confidence in financial stability and future growth.

What critics are saying

  • Increased competition in glucocorticoid market may challenge CRENESSITY's market position.
  • Financial burden from Osavampator development could impact Neurocrine's resources.
  • New CMO appointment may lead to strategic shifts misaligned with current goals.

What makes Neurocrine Biosciences unique

  • Neurocrine's CRENESSITY shows significant glucocorticoid dose reduction in CAH patients.
  • Exclusive rights to develop Osavampator outside Japan strengthens Neurocrine's MDD treatment portfolio.
  • Phase 3 trial of NBI-1117568 for schizophrenia highlights focus on neuropsychiatric disorders.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

Company News

PR Newswire
May 15th, 2025
Neurocrine Biosciences Presents Data On Improvements In Physiologic Glucocorticoid Dosing And Select Reproductive Hormones In Patients With Classic Congenital Adrenal Hyperplasia Taking Crenessity™ (Crinecerfont)

90% of Pediatric Participants on CRENESSITY versus 21% on Placebo Achieved ≥1 Threshold for Androstenedione Reduction or Glucocorticoid Reduction. Observed Rates of Select Reproductive Hormone Normalization in Adult Males Taking CRENESSITY with Substantial Glucocorticoid Dose Reductions. Findings Presented at the 2025 American Association of Clinical Endocrinology Annual MeetingSAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial proportion of pediatric patients with classic congenital adrenal hyperplasia achieved physiologic-range glucocorticoid doses and normal androstenedione levels. Additionally, adult male patients with classic congenital adrenal hyperplasia observed improvements in select reproductive hormone levels. Both adult and pediatric patients achieved substantial reductions in glucocorticoid doses. These results were presented at the 2025 American Association of Clinical Endocrinology Annual Meeting in Orlando

PR Newswire
May 14th, 2025
Neurocrine Biosciences Presents Findings Contributing To The Growing Body Of Evidence On The Impact Of High-Dose Glucocorticoids On Clinical Outcomes In Congenital Adrenal Hyperplasia

Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical OutcomesFindings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual MeetingSAN DIEGO, May 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including decreased bone mineral density, increased insulin resistance and higher body mass index, in patients with congenital adrenal hyperplasia. This study was presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting in Montreal, Canada.Congenital adrenal hyperplasia (CAH) is a rare, lifelong genetic condition linked to overproduction of adrenal androgens and cortisol deficiency. CAH is traditionally treated with lifelong high-dose glucocorticoids (GCs), which increase the risk of complications across multiple aspects of health. However, the relationship between GC dose and adverse clinical outcomes in CAH has not been fully explored. This systematic literature review was conducted to analyze the relationship between GC dose and clinical outcomes, and is the first to capture the impact of higher GC dose on the incidence and severity of all relevant adverse clinical outcomes in patients with CAH."CAH requires lifelong glucocorticoid therapy to manage adrenal androgen excess and cortisol deficiency, but high doses often lead to significant complications, including cardiometabolic, bone and growth issues," said Eiry W

Clinical Trial Vanguard
May 1st, 2025
Neurocrine Starts Phase 3 Trial of NBI-1117568 for Schizophrenia

Nxera Pharma's partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist, for schizophrenia treatment.

Contract Pharma
Apr 4th, 2025
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer

Neurocrine Biosciences Inc. has appointed Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.

BioSpace
Mar 12th, 2025
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

SAN DIEGO, March 11, 2025 /PRNewswire/ - Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025.